Sernova Biotherapeutics Income Statement

Financials in millions CAD. Fiscal year is November - October.

Millions CAD. Fiscal year is Nov - Oct.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Oct '25 Oct 31, 2025	Oct '24 Oct 31, 2024	Oct '23 Oct 31, 2023	Oct '22 Oct 31, 2022	Oct '21 Oct 31, 2021
Selling, General & Admin	7.52	8.97	8.46	7.86	2.3
Research & Development	7.5	22.69	32.04	16.9	4.64
Operating Expenses	15.02	31.66	40.5	24.75	6.94
Operating Income	-15.02	-31.66	-40.5	-24.75	-6.94
Interest Expense	-0.75	-0.59	-0.03	-0.05	-0.01
Interest & Investment Income	0.03	0.39	1.5	0.58	0.07
Currency Exchange Gain (Loss)	-0.04	-0.34	0.04	-0.13	-0.04
Other Non Operating Income (Expenses)	-	-	-	-0.07	-0.05
EBT Excluding Unusual Items	-15.79	-32.2	-39	-24.42	-6.97
Gain (Loss) on Sale of Assets	0.06	0.02	-	-	-
Pretax Income	-15.73	-32.19	-39	-24.42	-6.97
Income Tax Expense	0.01	0.01	-	-	-
Net Income	-15.74	-32.19	-39	-24.42	-6.97
Net Income to Common	-15.74	-32.19	-39	-24.42	-6.97
Shares Outstanding (Basic)	328	307	303	274	246
Shares Outstanding (Diluted)	328	307	303	274	246
Shares Change (YoY)	6.95%	1.19%	10.87%	11.43%	24.45%
EPS (Basic)	-0.05	-0.10	-0.13	-0.09	-0.03
EPS (Diluted)	-0.05	-0.10	-0.13	-0.09	-0.03
Free Cash Flow	-10.91	-18.9	-30.44	-14.75	-6.86
Free Cash Flow Per Share	-0.03	-0.06	-0.10	-0.05	-0.03
EBITDA	-14.77	-31.25	-40.19	-24.45	-6.69
D&A For EBITDA	0.26	0.41	0.31	0.3	0.24
EBIT	-15.02	-31.66	-40.5	-24.75	-6.94

Source: S&P Global Market Intelligence. Standard template. Financial Sources.